This review highlights the pro-atherogenic roles of Ca 2＋ -sensitive intracellular protease calpains. Among more than ten species of calpain isozymes, μ-and m-calpains have been characterized most extensively. These two isozymes are ubiquitously expressed in mammalian tissues, including blood vessels, and tightly regulate functional molecules in the vascular component cells through limited proteolytic cleavage. Indeed, previous cell-based experiments showed that calpains play significant roles in nitric oxide production in vascular endothelial cells (ECs), maintenance of EC barrier function and angiogenesis for maintaining vascular homeostasis. Recently, we demonstrated that modified-low density lipoprotein (LDL)-induced m-calpain causes hyperpermeability in ECs, leading to the infiltration of monocytes/macrophages and plasma lipids into the intimal spaces (Miyazaki T. et al., Circulation. 2011; 124: 2522-2532). Calpains also mediate oxidized LDL-induced apoptotic death in ECs. In monocytes/macrophages, calpains induce proteolytic degradation of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1), which results in impaired cholesterol efflux and subsequent macrophage foam cell formation. In vascular smooth muscle cells, calpains may be involved in the conversion from contractile phenotype to proliferative phenotype. In hepatocytes, calpains disrupt the biogenesis of high-density lipoprotein via proteolytic degradation of ABCA1. Thus, calpains may serve as novel candidate molecular targets for control of atherosclerosis. J Atheroscler Thromb, 2013; 20:228-237.
Introduction
Calpains, which are Ca 2＋ -sensitive intracellular cysteine proteases, tightly regulate their respective substrates through limited proteolytic cleavage. Calpains recognize various intracellular substrate molecules, thereby controlling cellular activities; consequently, numerous in vivo and in vitro experiments employing genetic and pharmacological approaches have focused on the roles of calpains. As a result, calpains have been identified as molecular targets for a variety of diseases, such as Alzheimer's disease 1) , ischemic stroke 2) and myocardial infarction 3) . Furthermore, the deleterious effects of calpains under conditions of cardiovascular disease, including hypertension 4) and diabetes mellitus 5, 6) , have been proposed. Recently, several lines of evidence published by us 7) and others [8] [9] [10] [11] [12] indicated pathophysiological implications of calpain systems in atherosclerotic diseases, although calpains are likely to participate in the physiological regulation of the vessels 13) . Accordingly, this review highlights the physiological roles of calpain systems, as well as their proatherogenic properties.
Atherosclerosis, a vascular disease characterized by functional and structural disorders in whole arterial trees, is often triggered by plasma dyslipidemia 14) . Plasma dyslipidemia itself is largely ameliorable with pharmaceutical agents such as statins. In addition to their original pharmacologic actions, statins may exert direct effects on vascular walls, e.g., anti-inflammatory effects, which is beneficial in the treatment of atherosclerosis 15) . Indeed, pharmacotherapy with statins has been shown to reduce significantly cardiovascular event rates in randomized, placebo-controlled clinical trials defects in embryos 27, 28) .
The aforementioned studies suggested that calpains can proteolyze a variety of functional molecules. Indeed, calpains cleave focal adhesion proteins including talin 29) and vinculin 30) , leading to alterations in cell motility and morphology. Furthermore, calpaininduced processing and functional modification of some signaling molecules (e.g., focal adhesion kinase 31) , protein kinase C 32) and inhibitor of κB [IκBα] 33, 34) ) have been described previously; thus, calpains proteolytically modulate cellular functions. For additional molecular and enzymatic details pertaining to calpain, refer to the excellent initial reviews published prior to the current article [18] [19] [20] .
Calpain and Vascular Integrity
Earlier investigations disclosed that both μ-and m-calpains are present in vascular component cells, including vascular endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). In particular, functional properties of calpain systems in ECs have been examined intensively. The majority of previous reports appear to support the notion that calpains act in ECs and ensure vascular integrity ( Fig. 1 and Table 1 ). It is likely that VEGF 35, 36) and fluid shear stress 13, 37, 38) are representative activators of calpain systems in ECs under physiological conditions. ECs exhibit measurable calpain activity even under unstimulated conditions 39, 40) , which may be due to spontaneous Ca 2＋ mobilization in the cells 41) . Mechanistically, calpainmediated regulation of small GTPases 13, 40) as well as calpain-induced proteolysis of focal adhesion proteins 37) during EC dynamics has been documented previously. Accordingly, calpain systems appear to play key roles in angiogenesis 36, 38) , wound closure 39) and maintenance of barrier functions 13, 40) in ECs. In addition to motility responses, it has been reported that nitric oxide (NO) production in ECs is modulated through calpain-induced proteolysis of HSP90 42) or calpain-regulated PI3K/AMPK signaling 35) . The physiological significance of these calpain-mediated responses in ECs, however, remains controversial since the observations were mainly derived from cell-based experiments. Further studies using animal models will be needed for better understanding of the physiological aspects of calpain systems. More importantly, it is likely that the calpain system in ECs under physiological conditions undergoes compensation given that systemic deficiency of CAPN1 23) and EC-specific deficiency of CAPN2 26) in mice employing gene-targeting techniques did not induce severe cardiovascular defects. Therefore, calpains can be regarded as molecular tar-in some instances; however, statins are not always necessarily sufficient for medical needs 16) . For example, recurrent ischemic events following acute coronary syndrome occur in ＞20% of patients by 36 months despite optimal cholesterol-lowering therapy and medical care 17) . Thus, the molecules expressed in the vascular walls, which function as critical factors for direct control of atherosclerotic cardiovascular diseases, should be targeted to achieve better therapeutic outcomes. Calpains may be regarded as potential molecular targets for control of atherosclerotic diseases; consequently, this article assesses the potency of calpains as a novel molecular target for atherosclerosis. To the best of our knowledge, this review article is the first to focus on the pathophysiological implications of calpain systems in atherosclerotic diseases.
Molecular Characteristics of Calpains
Calpains are classified into ubiquitous and tissuespecific isoforms 18, 19) . This review focuses on the ubiquitous subtypes, given that vessel-specific calpain has not been identified. Two major ubiquitous forms of calpain, μ-and m-calpain, require micromolar and millimolar levels, respectively, of Ca 2＋ for half-maximal activation 20) . These calpain isozymes are composed of heterodimers of the common regulatory subunit, CAPNS1 (CAPN4 or calpain-4), and the subtype-specific large subunits, CAPN1 (calpain-1 or μCL) and CAPN2 (calpain-2 or mCL), which serve as catalytic subunits of μ-and m-calpain isozymes, respectively. Both μ-and m-calpain subtypes can be activated intracellularly via biochemical sensitization, such as direct binding to phosphoinositide biphosphate 21) and extracellular signal-regulated kinase signals 22) . Deficiency of the CAPN1 gene in mice results in normal growth, albeit with a reduction in platelet aggregation and clot retraction 23) ; therefore, μ-calpain does not play a crucial role in the survival of a living body. In contrast, CAPN2-deficient mice appear to display embryonic lethality between the morula and blastocyst stages 24) . In a manner similar to CAPN2, deficiency of the CAPNS1 gene leads to an embryonically lethal phenotype 25) , which is accompanied by impaired cardiovascular development, suggesting a vital role of m-calpain. In contrast, Takano et al. recently revealed that conditional knockout mice, in which m-calpain is expressed in the placenta but not in the fetus, survive to adulthood 26) . Thus, m-calpain is unlikely to play an essential role in cardiovascular development in the fetus, but rather plays critical roles in placental integrity, since abnormalities in placental development have been shown to cause cardiovascular tension 4) and atherosclerotic vascular disease 7) . The biological implications of the differential roles of calpains under physiological and pro-atherogenic conditions remain unknown; however, we hypothesized that pathogenic mediators [e.g., modified low-density lipoprotein (LDL) in atherosclerosis, angiotensin Ⅱ in hypertension] lead calpains to an over-active state or otherwise abnormal elevation of expression, thereby accelerating pro-atherogenic conditions. Since previous studies focused on the calpain systems, in particular in ECs and monocytes/macrophages as key regulators in atherosclerosis, pro-atherogenic roles of calpain systems in these cells as well as their comprehensive mechanisms underlying atherosclerosis are summarized below.
Endothelial Cells
ECs exert physical barrier effects against immune gets for chronic inflammatory vascular diseases, such as diabetic vascular complications and atherosclerosis without causing serious unfavorable effects. Additional investigations regarding how the physiological actions of calpain are compensated are necessary in order to further the understanding of the calpain system in blood vessels.
Pro-Atherogenic Roles of Calpains
While calpains appear to ensure vascular integrity under physiological conditions as stated above, pathophysiological implications of calpains in terms of the cardiovascular system have been frequently noted. Indeed, calpain inhibitors reportedly ameliorate cardiovascular disorders in experimental animal models, including diabetic microvascular inflammation 5, 6) , vascular fibrosis during angiotensin Ⅱ-induced hyper- or chemokines [e.g., monocyte chemoattractant protein-1 (MCP-1)] 55) through inflammatory signals reportedly promotes the adhesion of monocytes to vascular ECs, which leads to increased atherosclerosis susceptibility in the artery 14) ; consequently, the inflammatory response in ECs is an important pathological feature of pro-atherogenic arteries. In particular, earlier studies focused on NF-κB signals as representative inflammatory signals in atherosclerosis 56, 57) . Interestingly, calpains are capable of promoting NF-κB signals via the degradation of IκBα without affecting phosphorylation of this inhibitor 33, 34) . Since m-calpain is induced in ECs in atherosclerotic lesions 7) , it is not surprising that NF-κB signals are promoted in ECs during atherogenesis through calpain-induced degradation of IκBα. This hypothesis is consistent with our previous data: the expression levels of NF-κB as well as those of adhesion molecules or cytokines in the pro-atherogenic aorta in ldlr −/− mice decreased significantly following administration of the calpain inhibitors, calpeptin and calpain inhibitor Ⅱ 7) . Moreover, calpain inhibitor BDM-410 reportedly exhibits similar anti-inflammatory effects in the aorta of angiotensin Ⅱ-induced abdominal aortic aneurism model mice 12) . Additional studies are necessary to determine whether calpain inhibitors interfere directly or indirectly with the inflammatory signals in ECs during the development of atherosclerosis.
Monocytes/Macrophages
Recruitment of monocytes into the intimal spaces and subsequent formation of foam cells from differentiated macrophages are a hallmark of atherosclerosis 14) . The pro-atherogenic role of calpain in macrophages has been described previously. ATP-binding cassette transporter A1 (ABCA1) in macrophages is reportedly inactivated by μ-calpain-induced proteolysis of the amino acid sequences enriched with proline, glutamic acid, serine and threonine (PEST sequence) 8) . Upon exposure of macrophages to apoA-I, binding of apoA-I to ABCA1 accelerated cholesterol efflux and inhibited calpain-mediated degradation of ABCA1. Lin et al. demonstrated that endothelin-1 treatment of oxidized LDL-stimulated rat bone marrow-derived macrophages leads to proteolytic degradation of ATPbinding cassette transporter G1 (ABCG1) by calpain, with no alteration of CD36 protein expression, scavenger receptor class B type I or scavenger receptor class A or ABCA1, which resulted in accelerating cholesterol accumulation in the cells 11) . Therefore, calpains are capable of interfering with cholesterol efflux from monocytes/macrophages via degradation of the ABC transporters; however, the actions of calpains in these cells or active constituents in plasma. During the early stage of atherosclerosis, EC barrier dysfunction leads to leakage of LDL and extravasation of monocytes into the intimal spaces, which accelerates atherosclerosis progression 14) . An earlier investigation determined that aortic VE-cadherin, a dominant factor in EC barrier function, lacks organization in ApoE −/− mice during the development of atherosclerosis 43) . We recently established that VE-cadherin disorganization is due to direct proteolysis by m-calpain in aortic ECs 7) . Interestingly, the subtype-selective induction of m-calpain occurs simultaneously in the pro-atherogenic aorta in mice, a phenomenon restricted to ECs on atheroma rather than other component cells in atherosclerotic lesions (e.g., VSMCs or foam cells). This observation is consistent with human atherosclerosis, since the EC-specific induction of m-calpain also occurs in atherosclerotic lesions in the human aorta. Given that down-regulation of VE-cadherin reportedly promotes extravasation of immunocompetent cells or macromolecules into the vascular wall 44, 45) and that in vivo silencing of CAPN2 by siRNA results in the prevention of pro-atherogenic hyperpermeability in the murine aorta 7) , it is likely that m-calpain-induced disorganization of VE-cadherin in aortic ECs may accelerate the progression of atherosclerotic lesions.
Modification of plasma LDLs, e.g., enzymatic hydrolysis by secretory phospholipase A2 (sPLA2) or direct oxidation by oxidative stress, is known to exert pro-atherogenic effects on vascular ECs. Indeed, oxidized LDL accelerates the induction of inflammatory markers 46) , barrier dysfunction 47) and apoptotic cell death in ECs 48) . Similarly, sPLA2-hydrolyzed LDL appears to facilitate the induction of adhesion molecules 49) . We recently demonstrated that treatment of HUVECs with either sPLA2-modified or oxidized LDL induced m-calpain expression, but not μ-calpain expression 7) . This subtype-selective induction of m-calpain is mimicked by treatment with lysophosphatidylcholine (LPC), a major oxidation product in modified LDL 50) , leading to cleavage of VE-cadherin in the cells. LPCinduced up-regulation of calpain is consistent with the previous report demonstrating that LPC treatment of cells resulted in the mobilization of intracellular Ca 2＋ and calpain-mediated cleavage of talin 51) . On the other hand, Pörn-Ares et al. previously showed that oxidized LDL-induced apoptotic cell death in human dermal microvascular ECs is inhibited by the calpain inhibitor, PD151746 52) , suggesting that calpains act on modified LDL-and LPC-induced signaling pathways in ECs during the development of atherosclerosis.
Induction of adhesion molecules (e.g., VCAM-1 and E-selectin) 53) , cytokines (e.g., TNF-α and IL-1) 54) play some roles in initial thickening and plaque instability under pro-atherogenic conditions; however, the implications of calpain systems in VSMCs in atherosclerosis are currently limited and have not been fully elucidated since the observations are derived from cellbased experiments. Direct evaluation employing atherosclerotic animal models or specimens obtained from patients with atherosclerosis is necessary in order to strengthen this hypothesis.
It is generally accepted that high-density lipoprotein (HDL) has apparently protective roles against atherosclerosis and subsequent coronary heart diseases, which is explained by the concept of reverse cholesterol transport. HDL could ferry cholesterol from the vessel wall to the liver for excretion to bile 62) . Since ABCA1 in hepatocytes is critical for biogenesis of HDL 63, 64) , many researchers have focused on hepatic ABCA1 as the molecular target for controlling atherosclerosis. Wang et al. previously reported that both helical apolipoprotein apoA-I and the calpain inhibitor calpeptin stabilize ABCA1 in hepatocytes 8) . The effect of apoA-I and calpain inhibition is additive with respect to stabilization of ABCA1 9) ; therefore, it is likely that down-regulation of calpains is involved in the apoA-I-induced stabilization of ABCA1. Hepatic ABCA1 degradation observed in cholesterol-fed rabbits decreases in the presence of an anti-oxidative hypolipidemic agent, probucol, which leads to increased HDL biogenesis, thereby ameliorating atherosclerosis 10) . It is interesting to hypothesize that probucol down-regulates calpains in hepatocytes. These findings are suggestive of the potential contribution of μ-calpain to hepatic ABCA1 degradation during atherogenesis.
Potency of Calpain as a Molecular Target in Atherosclerosis
A number of non-peptide calpain inhibitors are commercially available; moreover, several of these inhibitors have been employed in animal experiments for pharmacological intervention against cardiovascular diseases ( Table 1) . Calpains probably exert proatherogenic effects in various types of cells, including VSMCs and hepatocytes as well as vascular ECs and monocytes/macrophages, as described above ( Fig. 1  and Table 2) ; thus, it is not surprising that calpain inhibitors are effective against atherosclerotic disease. Rather, calpain inhibitors may be expected to function as candidate multifunctional anti-atherosclerotic drugs that can simultaneously ameliorate multiple pathological events in atherosclerosis, e.g., vascular inflammation in ECs and foam cell formation in macrophages. cells in atherosclerotic lesions in vivo have not been characterized fully. Consequently, it should be noted that the pro-atherogenic roles of calpain in monocytes/macrophages remain poorly understood.
Possible Mechanisms Underlying Acceleration of Atherosclerosis by Calpain Systems
Possible mechanisms underlying the acceleration of atherosclerosis by calpain systems are illustrated in Fig. 1 . As mentioned above, m-calpain actively participates in the dysfunction of EC barrier in the early phase of atherosclerosis 7) , probably leading to the infiltration of plasma LDLs into intimal spaces. Indeed, the m-calpain-dependent extravasation of macromolecules into subendothelial spaces was detectable in the aorta of ldlr −/− mice at least within 7 days following initiation of a high cholesterol diet 7) . In parallel with EC barrier dysfunctions, induction of pro-inflammatory genes, including adhesion molecules and MCP-1, may be facilitated in ECs through calpain-induced proteolytic degradation of IκBα 33, 34) . As a result of these calpain-regulated inflammatory responses in ECs, monocytes/macrophages are recruited into the intimal space, and subsequently scavenge the accumulated LDLs. During LDL processing, μ-calpain appears to proteolytically inactivate ABC transporters in macrophages 8, 11) , resulting in further enhancement of cholesterol accumulation and foam cell formation. Thus, it is likely that the calpain systems in ECs and monocytes/macrophages have significant roles in the development of atherosclerotic lesions. Interestingly, an earlier investigation disclosed that MCP-1 facilitates Ca 2＋ mobilization in adherent human monocytes 58) ; thus, we speculate that EC-derived humoral mediators may modify calpain activity in monocytes/macrophages in atherosclerotic lesions.
In addition to ECs and monocytes/macrophages, VSMCs are known to exhibit pro-atherogenic properties under the regulations of calpain systems. VSMCs present in vascular media are engaged in the modulation of systemic blood pressure and circulation via vasomotor actions under physiological conditions; these VSMCs undergo conversion from contractile phenotype to proliferative phenotype during the development of atherosclerotic lesions. The proliferative VSMCs, which likely migrate into atherosclerotic lesions, are implicated in the formation of fibrous caps over the lipid core; therefore, VSMC proliferation and motility are thought to be critical determinants of plaque instability in atherosclerotic lesions. Earlier investigations demonstrated that the spreading 59) , proliferation 60) and migration 61) of VSMCs are suppressed by calpain inhibition. Thus, calpains are expected to Given that atherosclerosis in mouse models is ameliorable by calpain inhibitors 7) , the clinical significance of anti-calpain therapy for atherosclerosis as well as its operating mechanisms merits greater examination. The normal growth of systemic CAPN1-deficient mice 23) and conditional CAPN2-deficient mice 26) is suggestive of the limited physiological roles of calpains in the cardiovascular system; nevertheless, the physiological relevance of calpains should be clarified by continuing investigations. This effort will be beneficial with respect to deeper insights into the possible adverse effects of calpain inhibitors.
Concluding Remarks
It is evident that calpains may be regarded as candidate molecular targets for atherosclerosis; however, identification of the key cell type that plays a dominant role in the progression of atherosclerosis under the control of the calpain systems remains a challenge. Advances in genetic approaches, including cell type-specific gene targeting employing the Cre-loxP system, will address this issue. Moreover, future investigations should focus on the actions of calpains in monocytes/macrophages, VSMCs and hepatocytes in atherosclerotic animal models. Subtype-selective calpain inhibitors may be highly desirable in order to achieve enhanced understanding of the disease mechanisms and improve therapeutic outcomes.
